hotspot -WSS

hotspot

author：fashion 2025-09-03 14:43:25 - browse：862

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Close Medicare's dangerous gaps in addiction treatment coverage

explore

WSS

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Bird flu outbreak in cows is latest avian flu curveball

Close Medicare's dangerous gaps in addiction treatment coverage

Orangutan used medicinal plant to treat wound, first time ever seen

Close Medicare's dangerous gaps in addiction treatment coverage

leisure time

hotspot

leisure time

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

State Dept. review finds Biden bears some blame for Afghanistan failures

Interest rates are at a 22

Wildfire smoke exposes gaps in outdoor worker protections

Hospitals, health systems can help patients avoid medical debt

Activists slam private health insurers over coverage restrictions

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

23andMe had bad news about my health. I wish a person had delivered it

Medical bills so high, Medicare adding extra digits to claim forms

explore

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

FTC falls short on scrutinizing hospital mergers, study says

Interest rates are at a 22

Biden jokes that Republicans may impeach him because inflation is starting to cool down

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

knowledge

explore

focus

knowledge